<code id='735382AC9C'></code><style id='735382AC9C'></style>
    • <acronym id='735382AC9C'></acronym>
      <center id='735382AC9C'><center id='735382AC9C'><tfoot id='735382AC9C'></tfoot></center><abbr id='735382AC9C'><dir id='735382AC9C'><tfoot id='735382AC9C'></tfoot><noframes id='735382AC9C'>

    • <optgroup id='735382AC9C'><strike id='735382AC9C'><sup id='735382AC9C'></sup></strike><code id='735382AC9C'></code></optgroup>
        1. <b id='735382AC9C'><label id='735382AC9C'><select id='735382AC9C'><dt id='735382AC9C'><span id='735382AC9C'></span></dt></select></label></b><u id='735382AC9C'></u>
          <i id='735382AC9C'><strike id='735382AC9C'><tt id='735382AC9C'><pre id='735382AC9C'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:fashion    Page View:722

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In